New Health and Mounjaro

Eli Lilly, the exclusive supplier of GLP-1 Mounjaro, has confirmed that New Health has risen from 3,048th to 29th place in its supplier list (by volume supplied). This has taken approximately three months since the Company's initial marketing campaign began.

Novo Nordisk, in written evidence to the House of Commons Health and Social Care Committee in August 2025, estimated that approximately 2 million people in the UK were using GLP-1 medicines for weight management, over 90 per cent. of them privately. New Health now has over 42,500 customers, representing approximately 2.1 per cent. of this market, up from more than 33,000 as at 30 September 2026

On the basis of Eli Lilly's ranking, the Directors consider New Health to be among the fastest growing GLP-1 providers in the UK and the Group remains on track to open its expanded GLP-1 line at Sarus Court by the end of October 2026, taking capacity to 14,000 orders a day.

Jason Drummond, Founder and Chief Executive Officer, commented:

"From 3,048th to 29th in three months. Eli Lilly's own ranking confirms the scale of what New Health has built since July. We now have more than 42,500 customers, representing approximately two per cent. of the UK's GLP-1 users.

"Two weeks ago we said repeat orders would grow as customers reached their first reorder date. They now make up over 30 per cent. of New Health revenue, up from 22 per cent. in September, with no acquisition cost attached. Our ambition is to be a top three UK GLP-1 provider. The expanded line at Sarus Court opens this month with capacity for 14,000 orders a day. This is what the Health OS was built for, and it is only the beginning."

The Directors of the Company are responsible for the contents of this announcement.